Cargando…
Targeting Platelet Activation Pathways to Limit Tumour Progression: Current State of Affairs
The association between cancer and a hypercoagulatory environment is well described. Thrombotic complications serve not only as a major mortality risk but the underlying molecular structure and function play significant roles in enhancing tumour progression, which is defined as the tumour’s capacity...
Autores principales: | , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9784118/ https://www.ncbi.nlm.nih.gov/pubmed/36558983 http://dx.doi.org/10.3390/ph15121532 |
_version_ | 1784857734192037888 |
---|---|
author | Xulu, Kutlwano R. Augustine, Tanya N. |
author_facet | Xulu, Kutlwano R. Augustine, Tanya N. |
author_sort | Xulu, Kutlwano R. |
collection | PubMed |
description | The association between cancer and a hypercoagulatory environment is well described. Thrombotic complications serve not only as a major mortality risk but the underlying molecular structure and function play significant roles in enhancing tumour progression, which is defined as the tumour’s capacity to survive, invade and metastasise, amongst other hallmarks of the disease. The use of anticoagulant or antiplatelet drugs in cardiovascular disease lessens thrombotic effects, but the consequences on tumour progression require interrogation. Therefore, this review considered developments in the management of platelet activation pathways (thromboxane, ADP and thrombin), focusing on the use of Aspirin, Clopidogrel and Atopaxar, and their potential impacts on tumour progression. Published data suggested a cautionary tale in ensuring we adequately investigate not only drug–drug interactions but also those unforeseen reciprocal interactions between drugs and their targets within the tumour microenvironment that may act as selective pressures, enhancing tumour survival and progression. |
format | Online Article Text |
id | pubmed-9784118 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-97841182022-12-24 Targeting Platelet Activation Pathways to Limit Tumour Progression: Current State of Affairs Xulu, Kutlwano R. Augustine, Tanya N. Pharmaceuticals (Basel) Review The association between cancer and a hypercoagulatory environment is well described. Thrombotic complications serve not only as a major mortality risk but the underlying molecular structure and function play significant roles in enhancing tumour progression, which is defined as the tumour’s capacity to survive, invade and metastasise, amongst other hallmarks of the disease. The use of anticoagulant or antiplatelet drugs in cardiovascular disease lessens thrombotic effects, but the consequences on tumour progression require interrogation. Therefore, this review considered developments in the management of platelet activation pathways (thromboxane, ADP and thrombin), focusing on the use of Aspirin, Clopidogrel and Atopaxar, and their potential impacts on tumour progression. Published data suggested a cautionary tale in ensuring we adequately investigate not only drug–drug interactions but also those unforeseen reciprocal interactions between drugs and their targets within the tumour microenvironment that may act as selective pressures, enhancing tumour survival and progression. MDPI 2022-12-09 /pmc/articles/PMC9784118/ /pubmed/36558983 http://dx.doi.org/10.3390/ph15121532 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Review Xulu, Kutlwano R. Augustine, Tanya N. Targeting Platelet Activation Pathways to Limit Tumour Progression: Current State of Affairs |
title | Targeting Platelet Activation Pathways to Limit Tumour Progression: Current State of Affairs |
title_full | Targeting Platelet Activation Pathways to Limit Tumour Progression: Current State of Affairs |
title_fullStr | Targeting Platelet Activation Pathways to Limit Tumour Progression: Current State of Affairs |
title_full_unstemmed | Targeting Platelet Activation Pathways to Limit Tumour Progression: Current State of Affairs |
title_short | Targeting Platelet Activation Pathways to Limit Tumour Progression: Current State of Affairs |
title_sort | targeting platelet activation pathways to limit tumour progression: current state of affairs |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9784118/ https://www.ncbi.nlm.nih.gov/pubmed/36558983 http://dx.doi.org/10.3390/ph15121532 |
work_keys_str_mv | AT xulukutlwanor targetingplateletactivationpathwaystolimittumourprogressioncurrentstateofaffairs AT augustinetanyan targetingplateletactivationpathwaystolimittumourprogressioncurrentstateofaffairs |